TickerFacts.

SAB Biotherapeutics, Inc. (SABS): Shareholders' Equity

Annual figures by period end, from SEC filings.

$151.49M
As of 2025-12-31
$214.78M
As of 2026-06-30
+69.6%
3-year compound annual growth
+31.2%
5-year compound annual growth
2020-12-31: $39.01M2021-12-31: $38.55M2022-03-31: $41.26M2022-06-30: $37.12M2022-12-31: $31.06M2023-12-31: $57.30M2024-12-31: $25.97M2025-12-31: $151.49M$151.49M
2020-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$151.49M+483.4%2026-03-09, Balance as of period end
2024-12-31$25.97M-54.7%2026-03-09, Balance as of period end
2023-12-31$57.30M+84.5%2025-03-31, Balance as of period end
2022-12-31$31.06Mn/a2024-03-29, Balance as of period end
2022-06-30$37.12Mn/a2023-04-14, Balance as of period end
2022-03-31$41.26Mn/a2023-04-14, Balance as of period end
2021-12-31$38.55M-1.2%2023-04-28, Balance as of period end
2020-12-31$39.01Mn/a2023-04-28, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
SAB Biotherapeutics, Inc. (SABS)2025-12-31$151.49M+483.4%
Sutro Biopharma, Inc. (STRO)2025-12-31-$132.45Mn/m
Caribou Biosciences, Inc. (CRBU)2025-12-31$122.17M-51.7%
Aura Biosciences, Inc. (AURA)2025-12-31$136.91M-9.9%
Cabaletta Bio, Inc. (CABA)2025-12-31$112.05M-26.4%
Inhibikase Therapeutics, Inc. (IKT)2025-12-31$172.90M+82.3%
Vaxart, Inc. (VXRT)2025-12-31$87.80M+49.0%
Editas Medicine, Inc. (EDIT)2025-12-31$27.29M-79.7%
Compugen Ltd (CGEN)2025-12-31$102.73M+87.1%

Compare SABS, STRO, CRBU, AURA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗